Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Curr Opin Support Palliat Care ; 15(4): 253-259, 2021 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-34726191

RESUMO

PURPOSE OF REVIEW: To provide a contemporary rationale for bladder preservation as a treatment strategy for muscle-invasive urothelial carcinoma of the bladder. Although the standard of care for this important and serious clinical condition has been radical cystectomy augmented with neoadjuvant systemic chemotherapy, it is associated with substantial morbidity and quality of life (QoL) implications. This article explores the bladder sparing alternatives to radical cystectomy and urinary diversion to assist Urologists, Medical Oncologists, and Palliative Care providers in their informed decision making with patients. RECENT FINDINGS: Bladder sparing strategies such as partial cystectomy and trimodality therapy offer long-term cancer outcomes comparable to radical cystectomy in carefully selected patients. Moreover, the toxicity profile in patients, having improved over time, is acceptable, including a low risk of salvage cystectomy. SUMMARY: Bladder preservation therapy offers an alternative to radical cystectomy. In some patients, it can be done with curative intent and in others it can assist with symptom palliation. Bladder preservation can maintain QoL and provide similar oncologic outcomes to radical surgery, although randomized controlled trials have not been performed. Understanding patient selection is a critical step in balancing bladder preservation and cancer survival.


Assuntos
Carcinoma de Células de Transição , Neoplasias da Bexiga Urinária , Cistectomia , Humanos , Invasividade Neoplásica , Qualidade de Vida , Resultado do Tratamento , Bexiga Urinária , Neoplasias da Bexiga Urinária/cirurgia
2.
Int J Radiat Oncol Biol Phys ; 100(4): 926-944, 2018 03 15.
Artigo em Inglês | MEDLINE | ID: mdl-29485072

RESUMO

Rectal cancer predominantly affects patients older than 70 years, with peak incidence at age 80 to 85 years. However, the standard treatment paradigm for rectal cancer oftentimes cannot be feasibly applied to these patients owing to frailty or comorbid conditions. There are currently little information and no treatment guidelines to help direct therapy for patients who are elderly and/or have significant comorbidities, because most are not included or specifically studied in clinical trials. More recently various alternative treatment options have been brought to light that may potentially be utilized in this group of patients. This critical review examines the available literature on alternative therapies for rectal cancer and proposes a treatment algorithm to help guide clinicians in treatment decision making for elderly and comorbid patients.


Assuntos
Algoritmos , Tomada de Decisão Clínica/métodos , Tomada de Decisões , Neoplasias Retais/radioterapia , Fatores Etários , Idoso , Braquiterapia/métodos , Quimioterapia Adjuvante , Comorbidade , Humanos , Participação do Paciente , Neoplasias Retais/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA